Literature DB >> 20724589

Two hypomorphic alleles of mouse Ass1 as a new animal model of citrullinemia type I and other hyperammonemic syndromes.

Carlos J Perez1, Jean Jaubert, Jean-Louis Guénet, Kirstin F Barnhart, Catherine M Ross-Inta, Vicente C Quintanilla, Isabelle Aubin, Jimi L Brandon, Nancy W Otto, John DiGiovanni, Irma Gimenez-Conti, Cecilia Giulivi, Donna F Kusewitt, Claudio J Conti, Fernando Benavides.   

Abstract

Citrullinemia type I (CTLN1, OMIM# 215700) is an inherited urea cycle disorder that is caused by an argininosuccinate synthetase (ASS) enzyme deficiency. In this report, we describe two spontaneous hypomorphic alleles of the mouse Ass1 gene that serve as an animal model of CTLN1. These two independent mouse mutant alleles, also described in patients affected with CTLN1, interact to produce a range of phenotypes. While some mutant mice died within the first week after birth, others survived but showed severe retardation during postnatal development as well as alopecia, lethargy, and ataxia. Notable pathological findings were similar to findings in human CTLN1 patients and included citrullinemia and hyperammonemia along with delayed cerebellar development, epidermal hyperkeratosis, and follicular dystrophy. Standard treatments for CTLN1 were effective in rescuing the phenotype of these mutant mice. Based on our studies, we propose that defective cerebellar granule cell migration secondary to disorganization of Bergmann glial cell fibers cause cerebellar developmental delay in the hyperammonemic and citrullinemic brain, pointing to a possible role for nitric oxide in these processes. These mouse mutations constitute a suitable model for both mechanistic and preclinical studies of CTLN1 and other hyperammonemic encephalopathies and, at the same time, underscore the importance of complementing knockout mutations with hypomorphic mutations for the generation of animal models of human genetic diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724589      PMCID: PMC2947290          DOI: 10.2353/ajpath.2010.100118

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  CITRULLINURIA.

Authors:  W C MCMURRAY; J C RATHBUN; F MOHYUDDIN; S J KOEGLER
Journal:  Pediatrics       Date:  1963-09       Impact factor: 7.124

2.  Brain-to-body ratios and time of maturation of the mouse brain.

Authors:  T KOBAYASHI
Journal:  Am J Physiol       Date:  1963-02

3.  Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice.

Authors: 
Journal:  Neuron       Date:  1997-10       Impact factor: 17.173

4.  Citrulline and ammonia accumulating in citrullinemia reduces antioxidant capacity of rat brain in vitro.

Authors:  Cristina C Prestes; Angela M Sgaravatti; Carolina D Pederzolli; Mirian B Sgarbi; Giovanni K Zorzi; Clóvis M D Wannmacher; Moacir Wajner; Angela T S Wyse; Carlos Severo Dutra Filho
Journal:  Metab Brain Dis       Date:  2006-04-27       Impact factor: 3.584

5.  Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia.

Authors:  Thomas Lücke; Dimitrios Tsikas; Nele Kanzelmeyer; Bernhard Vaske; Anibh Martin Das
Journal:  Metabolism       Date:  2006-12       Impact factor: 8.694

6.  Characterization of late-onset citrullinemia 1 in a Korean patient: confirmation by argininosuccinate synthetase gene mutation analysis.

Authors:  In-Suk Kim; Chang-Seok Ki; Jong-Won Kim; Munhyang Lee; Dong-Kyu Jin; Soo-Youn Lee
Journal:  J Biochem Mol Biol       Date:  2006-07-31

7.  Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis.

Authors:  M F Beal; R J Ferrante; S E Browne; R T Matthews; N W Kowall; R H Brown
Journal:  Ann Neurol       Date:  1997-10       Impact factor: 10.422

Review 8.  Nutritional management of urea cycle disorders.

Authors:  Rani H Singh; William J Rhead; Wendy Smith; Brendan Lee; Lisa Sniderman King; Marshall Summar
Journal:  Crit Care Clin       Date:  2005-10       Impact factor: 3.598

Review 9.  Urea cycle disorders: clinical presentation outside the newborn period.

Authors:  Wendy Smith; Priya S Kishnani; Brendan Lee; Rani H Singh; William J Rhead; Lisa Sniderman King; Michael Smith; Marshall Summar
Journal:  Crit Care Clin       Date:  2005-10       Impact factor: 3.598

10.  Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation.

Authors:  K Hensley; M L Maidt; Z Yu; H Sang; W R Markesbery; R A Floyd
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

View more
  9 in total

Review 1.  Animal models of human genetic diseases: do they need to be faithful to be useful?

Authors:  Jean-Louis Guénet
Journal:  Mol Genet Genomics       Date:  2011-05-06       Impact factor: 3.291

2.  l-Arginine Synthesis from l-Citrulline in Myeloid Cells Drives Host Defense against Mycobacteria In Vivo.

Authors:  Shannon M Lange; Melanie C McKell; Stephanie M Schmidt; Junfang Zhao; Rebecca R Crowther; Lisa C Green; Rebecca L Bricker; Eusondia Arnett; S Eleonore Köhler; Larry S Schlesinger; Kenneth D R Setchell; Joseph E Qualls
Journal:  J Immunol       Date:  2019-02-01       Impact factor: 5.422

3.  A novel biochemically salvageable animal model of hyperammonemia devoid of N-acetylglutamate synthase.

Authors:  Emilee Senkevitch; Juan Cabrera-Luque; Hiroki Morizono; Ljubica Caldovic; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2012-03-17       Impact factor: 4.797

4.  Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors.

Authors:  Rom Keshet; Joo Sang Lee; Lital Adler; Eytan Ruppin; Ayelet Erez; Muhammed Iraqi; Yarden Ariav; Lisha Qiu Jin Lim; Shaul Lerner; Shiran Rabinovich; Roni Oren; Rotem Katzir; Hila Weiss Tishler; Noa Stettner; Omer Goldman; Hadas Landesman; Sivan Galai; Yael Kuperman; Yuri Kuznetsov; Alexander Brandis; Tevi Mehlman; Sergey Malitsky; Maxim Itkin; S Eleonore Koehler; Yongmei Zhao; Keyur Talsania; Tsai-Wei Shen; Nir Peled; Igor Ulitsky; Angel Porgador
Journal:  Nat Cancer       Date:  2020-08-31

5.  A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria.

Authors:  Sandesh C S Nagamani; Oleg A Shchelochkov; Mary A Mullins; Susan Carter; Brendan C Lanpher; Qin Sun; Soledad Kleppe; Ayelet Erez; E O'Brian Smith; Juan C Marini; Brendan Lee
Journal:  Mol Genet Metab       Date:  2012-09-17       Impact factor: 4.797

6.  Sustained generation of nitric oxide and control of mycobacterial infection requires argininosuccinate synthase 1.

Authors:  Joseph E Qualls; Chitra Subramanian; Wasiulla Rafi; Amber M Smith; Liza Balouzian; Ashley A DeFreitas; Kari Ann Shirey; Benjamin Reutterer; Elisabeth Kernbauer; Silvia Stockinger; Thomas Decker; Isao Miyairi; Stefanie N Vogel; Padmini Salgame; Charles O Rock; Peter J Murray
Journal:  Cell Host Microbe       Date:  2012-09-13       Impact factor: 21.023

7.  Cytosolic Delivery of Argininosuccinate Synthetase Using a Cell-Permeant Miniature Protein.

Authors:  Susan L Knox; Rebecca Wissner; Samantha Piszkiewicz; Alanna Schepartz
Journal:  ACS Cent Sci       Date:  2021-03-18       Impact factor: 14.553

8.  Liver-directed adeno-associated virus serotype 8 gene transfer rescues a lethal murine model of citrullinemia type 1.

Authors:  R J Chandler; T N Tarasenko; K Cusmano-Ozog; Q Sun; V R Sutton; C P Venditti; P J McGuire
Journal:  Gene Ther       Date:  2013-10-17       Impact factor: 5.250

9.  Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53.

Authors:  Takafumi Miyamoto; Paulisally Hau Yi Lo; Naomi Saichi; Koji Ueda; Makoto Hirata; Chizu Tanikawa; Koichi Matsuda
Journal:  Sci Adv       Date:  2017-05-19       Impact factor: 14.136

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.